Indirect hyperbilirubinemia with indinavir

P. Satija, Falguni Parikh, V. Aggarwal, B. Sharma, Avi Hakim, J. V. Pai-Dhungat

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

Indinavir is a protease inhibitor used in the treatment of HIV infected individuals and as post-exposure prophylaxis. Indinavir is associated with various adverse effects including gastrointestinal, a lipodystrophy syndrome and nephrolithiasis. We describe indirect hyperbilirubinemia as an adverse effect of indinavir in a person on post-exposure prophylaxis (PEP).

Original languageEnglish (US)
Pages (from-to)1316-1317
Number of pages2
JournalJournal of Association of Physicians of India
Volume50
Issue number10
StatePublished - Oct 2002

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Indirect hyperbilirubinemia with indinavir'. Together they form a unique fingerprint.

Cite this